COVID-19 response: Building the infrastructure

 

Building the infrastructure

Two infrastructure projects underway at the NRC’s Royalmount site in Montréal will help support Canada’s biomanufacturing production capacity. As a combined capability across the value chain of biologics research, development and production, the Biologics Manufacturing Centre and the clinical trial material facility will strengthen overall biomanufacturing capacity and pandemic readiness in Canada.

Biologics Manufacturing Centre

Construction is complete on a new GMP-compliant biomanufacturing facility - the Biologics Manufacturing Centre - on the NRC’s Royalmount site in Montréal. It will be used to manufacture vaccines, including the COVID-19 vaccine, and other biologics for large-scale human use.

Learn more about the Biologics Manufacturing Centre

Clinical trial material facility

The NRC is building a new permanent, GMP-compliant clinical trial material facility at its Royalmount Avenue site in Montréal. When complete, this facility will be used to manufacture vaccine and other biologic materials for clinical trials, to support vaccine development at the clinical trial stage.

Learn more about the clinical trial material facility

Key facts: The Biologics Manufacturing Centre and the clinical trial material facility

There are two separate projects underway at the NRC’s Royalmount site in Montréal that will help support Canada’s biomanufacturing production capacity. Find out more about the similarities and differences between these two facilities.

Learn more about the Key facts